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Abstract 
Objectives: The question whether mental illness prevalence rates are increasing is a controversially 
debated topic. Epidemiological articles and review publications that look into this research issue are 
often compromised by methodological problems. The present study aimed at using a meta-analysis 
technique that is usually applied for the analysis of intervention studies to achieve more 
transparency and statistical precision. 
Methods: We searched Pubmed, PsycInfo, CINAHL, Google Scholar and reference lists for repeated 
cross-sectional population studies on prevalence rates of adult mental illness based on ICD- or DSM-
based diagnoses, symptom scales and distress scales that used the same methodological approach at 
least twice in the same geographical region. The study is registered with PROSPERO 
(CRD42018090959). 
Results: We included 44 samples from 42 publications, representing 1,035,697 primary observations 
for the first time point and 783,897 primary observations for the second and last time point. Studies 
were conducted between 1978 and 2015. Controlling for a hierarchical data structure, we found an 
overall global prevalence increase odds ratio of 1.179 (95%-CI: 1.065 – 1.305). A multivariate meta-
regression suggested relevant associations with methodological characteristics of included studies.  
Conclusions: We conclude that the prevalence increase of adult mental illness is small and we 
assume that this increase is mainly related to demographic changes.  
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Summations 
• The issue of potentially increasing prevalence rates of mental illness is controversial. 
• Using a meta-analysis, we found a small increase of prevalence rates over time. 
• The increase may be due to demographic changes in current societies. 
Limitations 
• There is a scarcity of data from non-western regions. 
• The coverage of mental illness is unevenly distributed. 
• No data on prevalence changes of psychosis/schizophrenia were available. 
 
Data availability statement 
The data will be made available after publication.  
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Introduction 
Currently, numerous media reports and many lay and expert commentators suggest a belief that 
distress in general and mental illness more specifically are on the rise 1-3. These claims are usually 
supported by data on utilization of mental health care and by monitoring of health-related indicators 
such as suicides. The claim of rising mental illness – if supported by rigorous research – would have 
important implications not only for public mental health in terms of potential failure of treatment 
approaches 4 but also for wider society in terms of understanding living conditions that sociologists 
see to be deteriorating and stress terminologies such as social suffering or social pathology 5.  
Empirical research has supported these claims previously by utilizing a variety of study designs and 
indicators. But those studies and indicators have considerable methodological problems when it 
comes to generalizing trends of mental illness. Early epidemiological field studies from the 1980s on 
lifetime prevalence of depression have indicated higher prevalence rates in more recent birth 
cohorts 6,7. However, as later re-analyses have shown, the studies were compromised by recall bias 
8,9. Current psychiatric utilization rates are on the rise in many countries. Antidepressant 
consumption has doubled in OECD-countries between 2000 and 2015 10 and the rates of disability 
pensions claimed due to mental illness have increased in recent decades in the UK 11, Australia 12, 
Switzerland 13 and many other countries. The interpretation of rising utilization rates is, however, not 
straightforward. Increasing prescription rates may indeed indicate rising prevalence, but they may 
also indicate an increasing willingness to receive treatment in the population or more overuse and 
off-label use 14,15. The rise of disability pensions rates due to mental illness may be a mirror of a 
changing labour market with less physically damaging workplaces 16. Next, the WHO Global Burden of 
Disease-studies have stressed the increasing burden due to depression and other mental disorders 17. 
But the increasing burden caused by mental illness is not necessarily caused by an increasing 
prevalence, but may rather be due to changing demographics 18. Finally, the United States are 
currently experiencing a large-scale mental health-related crisis due to prescription and self-
administration of opioids 19. There is, yet, a clear indication that prescription and marketing practices 
have greatly contributed to this crisis.  
Many systematic reviews, utilizing different methodological approaches, have however not 
supported the assumption of increasing prevalence rates over time. Wittchen et al. reviewed review-
papers and re-analysed prevalence data for Europe and identified no relevant changes in recent 
years 20. Steel et al. reported a higher prevalence of common mental illness in the 1990s compared to 
the 2000s when analysing single-point cross-sectional studies 21. Using the Global Burden of Disease 
(GBD)-approach that is based on a variety of methodologies, Baxter et al. rejected the claim of a 
mental illness increase 18.  
Repeated cross-sectional studies, utilizing the same instruments and sampling methodologies over at 
least two timepoints, are currently regarded as the gold-standard for this type of research 22. 
Longitudinal cohort studies have the main disadvantage that they cover the ageing process of the 
sample while repeated cross-sectional samples can only differ in terms of demographics. Richter et 
al. found no clear trend in terms of prevalence changes when systematically reviewing repeated 
cross-sectional studies 23,24. Similarly, Jorm et al. searched for papers on common mental illness that 
covered more than one time point in Australia, Canada, the UK and the US and found no relevant 
prevalence changes 25. 
The most recent Global Burden of Disease-analysis utilized a different metric when looking into 
change of mental illness burden. According to this report, the percentage of years lived with 
disability (YLD) due to mental illness increased globally by 13.5% between 2007 and 2017. However, 
when age-standardisation was applied to account for demographic changes, the YLD percentage 
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decreased significantly by 1.1% 26. YLD percentage changes of substance use disorders were also 
affected by demographic changes. While the unstandardized percentage increased from 2007 to 
2017 by 16.7%, the age-standardized percentage changes were much lower (2.9%). Furthermore, the 
increase was mainly due to opioid use disorders, whereas alcohol use disorders decreased 
significantly during this time. 
 We searched the Global Health Data Exchange database (www.ghdx.healthdata.org) for global 
prevalence changes over the longer time period between 1990 and 2017. The search yielded the 
following results. The prevalence of mental disorders, not standardized for age, increased 
significantly by 2.47% but the age-standardized prevalence decreased significantly by 1.72%. 
Substance use disorder prevalence, not standardized for age, increased significantly by 5.65%, while 
the age-standardized prevalence increased non-significantly by 0.05% (see permanent link at the end 
of the article).  
A major methodological weakness of the GBD-approach is the use of meta-regression modelling and 
estimation processes. For example, the GBD reports provide population-based prevalence data for 
schizophrenia for every country in the world but only very few studies have actually analysed 
schizophrenia prevalences in the general population. Most prevalence studies on this disorder are 
based on hospital and register data. Given the relatively opaque data processing in the GBD study, 
compared to a black box by some researchers recently 27, there is a need for more precise and 
transparent estimates in terms of prevalence changes for mental illness using the gold-standard 
design noted above.  
Aims of the study 
Our study aims at conducting a systematic review and meta-analysis based on repeated cross-
sectional population surveys focusing on any adult mental illness prevalence changes over time. By 
using the term mental illness, we will refer throughout to mental disorders and distress to 
encompass the wide range of mental phenomena within the literature. We restricted this study to 
adults because data gathering procedures in children and adolescent populations (i.e. parent and 
teacher interviews) differ fundamentally from the procedures in adult populations where 
respondents report directly about their personal health.  
 
Methods 
Search strategy and data extraction 
The current study was registered with PROSPERO (registration number CRD42018090959; 
https://www.crd.york.ac.uk/PROSPERO). We searched the Pubmed, PsycInfo, CINAHL and Google 
Scholar databases. Reference lists were also searched. Inclusion criteria were publications on 
repeated cross-sectional studies with at least two time points on any kind of mental illness in adult 
populations (18 years+). We included a variety of methodological approaches for case definitions 
that were not restricted to DSM- or ICD-frameworks. This was because both the DSM-/ICD-
classifications are increasingly challenged 28 and the use of community survey instruments related to 
them is not uncontroversial 29,30, especially with regard to case ascertainment 31. We therefore used 
clinical diagnostic interviews (for both specific disorders and for all disorders combined), validated 
self-report symptom scales not used for diagnosis (e.g. Patient Health Questionnaire, PHQ-9), and 
distress assessment instruments (e.g. General Health Questionnaire, Kessler-6-Scale). Distress 
assessment instruments were included because they have been shown to be discriminative in terms 
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of DSM disorder caseness 32. Included languages were English, French, German, Dutch and Spanish. 
We did not apply any time restrictions or geographical restrictions.  
Exclusion criteria were as follows: longitudinal and cohort studies which assessed the same 
population at both time points; treatment prevalence studies (incl. consumption of medication or 
prescriptions) as treatment is not a valid proxy for illness; studies not at the core of the mental illness 
construct, e.g. substance use/misuse, psychosomatic symptoms or personality traits; studies covering 
the prevalence of somatic outcomes linked to mental illness (e.g. liver cirrhosis or mortality); studies 
on suicides, suicidality or self-harm, dementia and related cognitive conditions where specific 
analyses are already available 33,34.  
The initial search process was conducted by DR and was cross-checked by other project members. 
The study selection process was conducted by AW and AB who independently read abstracts and full 
texts. Disagreement on inclusion was resolved by consulting the senior project members (DR and 
RW).  
We conducted a quality appraisal of all included studies. As the currently available instruments were 
not suitable for our purposes of appraising repeated cross-sectional population studies, we adapted 
an instrument by Munn et al. 35. Our appraisal tool awarded higher scores for: national 
representativeness; coverage of ages from 18 to 70 years; census or random sampling; sample size 
greater than 1,000 per time point; comprehensive data on subjects and settings; response rate of at 
least 80 percent or more or of at least 50 percent with reasons; utilization of a DSM- or ICD-related 
tool or any other validated instrument; identical procedure at both timepoints; appropriate statistical 
analysis. Quality appraisal was conducted by AW and AB; disagreement was again resolved by DR or 
RW.  
Data extraction was conducted by DR and cross-checked by other team members. The following data 
were entered into a database: authors, publication year, country, world region, first datapoint year, 
second/last datapoint year, mental health condition (depression, anxiety etc.), type of assessment 
(clinical diagnosis, symptoms, distress), number of cases per timepoint, sample size per timepoint, 
number of years between first and last year, and quality appraisal score. In studies where only case 
percentages were reported with no raw data, we calculated the number by applying the percentage 
to the total sample size.  
Meta-analysis 
The meta-analysis was conducted utilizing a methodology usually applied to intervention studies that 
compare intervention and control conditions with odds ratios and 95%-confidence intervals (CI 
hereafter) as the effect size metric. Conceptually, therefore, the first time point constituted a 
baseline or control assessment and the second or last time point was comparable to a post-
intervention assessment to find out whether changes have occurred. In other words, we considered 
‘time’ as a form of intervention. We used the ‘meta’ (version 4.9-1) and ‘metafor’ (version 2.0-0) 
packages 36,37, R software (version 3.5.1) for all analyses 38. A random-effects-model with Paule-
Mandel-method for between-study variance estimation was used 39,40. Heterogeneity was assessed 
with the Q-Test. 
The ‘rma.mv’-function from the ‘metafor’-package was used for multilevel analyses to account for 
non-independence of some studies (i.e. publications nested within studies or the use of data from 
one time point for comparisons with several later time points in various publications). For example, 
we found several publications assessing different mental health conditions using the same data from 
the US ‘National Epidemiologic Survey on Alcohol and Related Conditions’ or the US ‘National Survey 
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on Drug Use and Health’. Due to the multilevel data structure of some samples we will indicate 
whether we report clustered or non-clustered analyses.  
Forest plots cannot be provided for the full sample of publications because of the dependent data 
structure. We will, however, provide a forest plot that – in cases of multiple papers per study – 
shows either the first publication from the study or the publication with highest sample size when 
more than one paper in the same year was published.   
Finally, we conducted a multivariate meta-regression to analyse the moderators’ association with the 
heterogeneity of the dependent effect size, accounting for the multilevel data structure. For this 
analysis we used again the rma.mv-function from the R package ‘metafor’. This function allows the 
computing of a multilevel model that adds a random effect for the study from where multiple papers 
have been published.  The R package ‘glmulti’ in combination with the package ‘metafor’ with a 
small-sample corrected Akaike Information Criterion was used for model selection. Publication bias 
was assessed by a contour-enhanced funnel plot and Egger’s Test 41. There was no funding source for 
this study. 
 
Results 
Our search identified 8545 publications from the databases and further 60 publications from 
reference lists. We assessed 109 publications in full text and included 44 samples from 42 
publications into the meta-analysis (see Table 1 and Figure 1 for PRISMA flowchart). Altogether, 
1,035,697 primary observations were included for the first time point and 783,897 primary 
observations for the second and last time point.  
We identified the following study characteristics: 20 samples were from Western Europe, 16 from 
North America, 3 each from Asia and Oceania and one each from the Middle East and from South 
America. Four samples used DSM/ICD-related clinical interviews for the entire range of mental 
disorders (excluding schizophrenia) and 20 samples utilized DSM/ICD-related clinical interviews on 
single disorders. Seven samples used symptom scales and 13 samples used distress scales. Due to the 
methodological similarity, we analysed symptom scales and distress scales below as one 
methodological approach. Prevalence changes of general mental illness were analysed in 4 samples, 
distress was analysed in 13 samples and 27 samples examined specific symptoms (15 samples looked 
for depression/depressive symptoms, 5 for drug dependence, 3 for alcohol dependence, and one 
each for anxiety, bipolar disorder, eating disorders, and medication dependence). The mean time 
between first and last data collection point was 9.9 years (median 10 years). Our quality appraisal 
resulted in 3 samples achieving 9 points, 8 samples 8 points, 13 samples 7 points and 20 samples less 
than 7 points. The visual inspection of the publication bias contour-enhanced funnel plot (Figure 3) 
revealed an asymmetry that was supported by a significant Egger’s test (p = 0.007). The funnel plot 
does not indicate an association between smaller sample size (i.e. higher standard error) and effect 
size and significant result.  
The main result is as follows: For all samples combined and accounting for dependence (i.e. clustered 
data) we found a univariate pooled odds ratio (OR) of 1.179 (CI 1.065 – 1.305). However, the Q-Test 
for heterogeneity was highly significant (Q(df = 43) = 1693.1, p < .0001). A forest plot that contains all 
single study publications and one publication each from a multiple paper study is provided in Figure 
2. 
As indicated by the univariate moderator analysis in Table 2, we found the following ORs for the 
different conditions: general mental illness: 1.046 (CI 0.998 – 1.097), distress: 1.126 (CI 0.946 – 
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1.340), depression: 1.298 (CI 1.062 – 1.587), alcohol dependence: 1.016 (CI 0.851 – 1.215), drug 
dependence: 1.999 (CI 1.155 – 3.459), medication dependence: 1.679 (1.187 – 2.374), anxiety: 1.449 
(CI 1.055 – 1.989), bipolar disorder: 2.836 (1.599 – 5.029), eating disorders: 0.906 (CI 0.634 – 1.294). 
We have conducted a univariate analysis (Table 2) and a multivariate meta-regression (Table 3). In 
the univariate analysis we found at least one significant odds ratio in every covariate. For example, 
we found significant ORs indicating increasing prevalence rates for self-report symptoms/distress, 
several mental illness conditions, world regions Asia, and Middle East, survey start decades 1970s 
and 1990s, all survey end decades, study periods 6 to 10 years and 16 to 20 years and quality score 8 
to 9 points. 
According to the model selection procedure we dropped the ‘start decade’ variable from the final 
regression model. In the multivariate analysis we found a reduced number of significant moderator 
variables. Additionally, some variables showed declining Ratio of Odds Ratios (RORs) and estimates 
when compared to reference categories, while the univariate analyses suggested otherwise. Self-
report symptoms/distress ORs indicated a significant increase in the univariate analyses whereas the 
other methodological approaches did not. In the multivariate analysis, however, we found a 
significant decreasing ROR and negative estimate for self-report symptoms/distress. Further 
significant RORs and negative estimates were found for illness conditions alcohol dependence and 
drug dependence (reference: general mental illness) and the end decade 2000s (reference: 1990s). 
Increasing significant RORs and positive estimates were found for the Middle East region (reference: 
Western Europe) and quality score 6 to 7 points (reference: 4 to 5 points). One predictor (mental 
illness condition ‘distress’) was dropped from the model by the statistics software due to 
redundancy. This happens in cases where there is an insufficient number of data points to estimate 
each coefficient.  
 
Discussion 
We have conducted a meta-analysis and a meta-regression on prevalence changes in adult mental 
illness since the 1970s. Overall, we found evidence of a small but significant increase over time (OR 
1.18). This result is based on studies that are very heterogeneous in their characteristics and in their 
outcomes.  While our funnel plot does not suggest that there is a ‘small study effect’ present as is 
known from trial meta-analyses, we cannot rule out a publication bias. Although prevalence studies 
are supposed to be less likely biased than intervention studies, it remains possible that some studies 
have not been published that, for example, have not found an increase of prevalence rates. 
Before discussing our results against the background of previous research, several limitations of our 
analysis need to be acknowledged. Firstly, as quite often with global epidemiological analyses, the 
publications used in our data set are based overwhelmingly on samples in Western Europe and North 
America. Hence, firm conclusions on other world regions cannot be made due to a shortage of 
studies, sometimes with only one relevant publication that has met our inclusion criteria. Secondly, 
the coverage of mental illness conditions is unevenly distributed with depression and distress the 
most commonly surveyed conditions in the original studies. Again, some other conditions were 
covered by only one study which restricts any conclusions that can be drawn. Thirdly, we did not find 
any study on psychosis/schizophrenia that has been conducted using a repeated cross-sectional 
design as required by our inclusion criteria. Thus, there is no information available on this very 
important diagnostic group. Fourthly, we cannot make any claims on subgroups within each sample, 
e.g. in terms of gender or age, where different trends may have occurred. Previous reviews have 
shown that such subgroup variations exist 23,24. Fifthly, as our analytical approach is focussed on the 
bigger picture of prevalence change for adult mental illness over time, we cannot rule out that there 
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are temporal fluctuations in terms of prevalence changes between the two time points that we used 
in our analysis. Again, previous reviews have shown that this is the case 23,24. Sixthly, we cannot make 
any claims about developments in specific countries or regions that lead to contradictory results, e.g. 
during times of severe economic recession.  
Additionally, we have to stress methodological issues inherent to meta-analysis and meta-regression 
in terms of identifying relevant moderator variables that are associated with the effect size. Meta-
analysis and meta-regression have to deal with the same constraints as other statistical procedures, 
namely the problems of multiple comparisons and statistical power in regression analyses 42,43. 
Simulation research has shown that the predictive power of mixed-effects meta-regression models, 
such as in our case, mainly relies on the number of studies and on the number of participants in the 
included studies. With more than 40 samples in the regression analysis, and with a comparatively 
high number of primary observations, we fulfil the basic requirements that are recommended in the 
methodological literature 44. However, we have to acknowledge that our data were not sufficient to 
avoid the deletion of some variables during the regression analysis. Additionally, meta-regression 
analyses are prone to the risk of spurious and false positive findings 45. In our meta-regression we 
found only one world region (Middle East) with a significantly positive estimate compared to the 
reference region of Western Europe. As this finding is based on only one study, we have to caution 
against any firm conclusion from this particular result. Finally, the variables in our analyses are 
heterogeneous in themselves across the included studies and we found some inconsistency when 
cross-tabulating world regions with mental illness conditions or other variables. However, we 
decided to keep the global perspective rather than excluding some regions with few available 
studies. 
Keeping these limitations in mind and seen from a broader perspective, our results, using a new 
methodology, are in line with previous reviews and aggregate analyses. As outlined in the 
introduction, most such publications have not supported the public impression that mental illness 
prevalence is on the increase 18,20,23,24,46. In addition, several meta-analyses on changes in anxiety and 
depression population mean scores over time have reported mixed results, questioning a clear 
tendency towards increasing anxiety and depression in western populations 47-49. 
Finally, we would like to stress the similarity of our results with the latest GBD-report. As outlined in 
the introduction of this article, that report 26 and the related prevalence data 
(www.ghdx.healthdata.org) suggested a small increase in years lived with disability and illness 
prevalence over time. However, when age-standardization is applied the increase is no longer 
apparent, and some illnesses are on the decline. Our results also do indicate only a small increase. As 
our data cannot be standardized or adjusted to age-related demographics, we assume that the small 
increase in our study may also be related to population ageing or other demographic changes.  
Beyond these previous reviews and aggregate analyses, our study is able to provide a more precise 
estimate of the likelihood of prevalence changes in mental illness for adults as we have only included 
studies utilizing an identical methodology on at least two time points in combination with a meta-
analytical estimation of prevalence changes. In addition, further strengths are that we captured a 
very high number of primary observations and included a variety of methodological approaches for 
case ascertainment. We also accounted for the multilevel data structure and conducted a 
multivariate meta-regression of publication and study characteristics. 
Concerning the meta-regression, we found relevant differences between the univariate and the 
multivariate approaches. Whether these differences are based on ‘true’ publication characteristics or 
on methodological artefacts, is difficult to determine. Methodologists caution against firm 
conclusions from multivariate meta-regressions 42. We have to deal with a methodological dilemma: 
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on one hand, a study on specific mental health problems at a specific time in a particular country 
conducted with a high-quality methodology is not sufficient to generalize its results as they may be 
limited to this time and place. One the other hand, the multitude of factors that impact mental illness 
prevalences makes it very difficult to isolate specific characteristics that may be responsible for 
changing or non-changing prevalence rates. 
Looking at concordant estimates, this suggests that prevalence changes in mental illness are only to a 
minor degree affected by the methodological approach and by the specific mental illness. 
Concordant estimates between the univariate and multivariate analyses suggest the following: 
prevalence changes are affected to some extent by the region where the study was conducted. The 
historical period may be of more importance with earlier decades showing higher prevalence 
changes although the length of the study period does not seem to be linearly associated to the 
prevalence changes. However, higher study quality is associated with identifying such changes. 
Our main result of a small increase in mental illness prevalence is obviously at odds with the evidence 
of a tremendous increase in mental health care utilization especially in the developed countries. One 
reason for the increase in the number of treated persons may be success in closing the treatment 
gap between those in need and those already in treatment 50. While this gap clearly exists from the 
perspective of conventional psychiatry, some experts have assumed that the increase of care 
provision should have reduced the prevalence of illness 4,25 – and this obviously has not been the 
case. However, the contrary claim that the increased provision of psychopharmacological treatment 
has led to an epidemic of mental disability is not supported by our results, either 51.  
Given the extension of mental health care provision and the public impression of a mental health 
epidemic during the same period, further research is needed to analyse the drivers of both 
developments. Several reasons have been proposed in recent publications, e.g. the de-stigmatization 
of specific mental disorders or the increasing willingness of primary care professionals to address 
mental illness in clinical encounters 18,24,46. In terms of utilization, another major driver might have 
been a sociocultural change that social scientists have called ‘psychologization’ 52, which involves the 
expansion of a “Therapy Culture” 53 into the general population. Alongside the common perception 
of recent massive social change resulting in an accelerating pace of everyday life, this therapy culture 
is assumed to be one important factor for a heightened willingness to report distress and to accept 
psychological and psychiatric treatment. The psychologization of everyday problems such as family 
conflicts or workplace problems may also have led to a perception of increased distress that for 
unknown reasons has not resulted in a large-scale increase in mental illness. Which combination of 
factors eventually leads to an increase of reported utilization rates remains difficult to determine and 
may be different in different countries. 
We conclude from our data that the prevalence of adult mental illness has increased minimally in 
recent decades and we assume that this increase can be best explained by demographic changes as 
suggested by the GBD data. From a methodological perspective, we conclude that research on 
changes in mental illness prevalence is faced with a similar situation to that which is encountered 
when considering the difference between single trials and meta-analyses. A meta-analysis has the 
advantages of providing greater statistical precision, dealing with contradictory findings and 
estimating study heterogeneity. As we have seen in our analysis, it is also necessary to account for 
the non-independence of several publications that stem from the same data set. Thus, the question 
of whether mental illness prevalence is generally changing or not cannot reliably be answered by one 
study or even by a small number of studies. Furthermore, this calls into question any attempt to 
extrapolate from one disorder (e.g. depression) to mental illness in general. Like in the GBD data, we 
have seen in our results that different illness conditions may develop in varied ways with the 
prevalence of one illness condition increasing while others are decreasing.  
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In addition, the obvious differences between the univariate and the multivariate moderator analysis 
highlight the methodological issues related to the analysis of prevalence changes over time. The 
results of single studies may indicate a prevalence change in a specific region. However, the 
prevalence change may also be related to the choice of methodological approach, the illness 
condition, the timing of the start and end of the survey, the length of the survey period or the overall 
study quality and combinations of those study characteristics. 
With our results and with the GBD results, we now have two different methodologies based on 
different data sources that suggest similar conclusions. From a current public health perspective, we 
can be rather confident that the overall global prevalence of mental illness has not dramatically 
increased in recent decades if it has at all. However, having found that there was no substantial 
increase in mental illness prevalence in recent decades, this does not indicate that mental illness 
should not be taken seriously. Nevertheless, the parallel trends of increasing mental health care 
utilization and stable prevalence rates suggests that the treatment gap is slowly closing in many 
countries. 
 
Appendix: Global Burden of Disease prevalence rates – Permanent link 
http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2017-
permalink/0b62acc85fbb00019b66a69face0b39d 
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Figure 1: Flow-Chart according to PRISMA 
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Figure 2: Forest Plot 
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Figure 3: Contour-enhanced Funnel Plot 
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et al. 
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Baumeister 
et al. 
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et al. 
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et al. 
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Dona et al. 
201360 
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de Graaf et 
al. 201261 
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et al. 
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Fu et al. 
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al. 201064 
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Clinical Interview 7 
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et al. 
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Källmen et 
al. 201168 
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et al. 
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Kessler et 
al. 200570 
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Kosidou et 
al. 201071 
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Kraus et al. 
201072 
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21.40 19.70 AUDIT, Alcohol misuse Clinical Interview 7 
Madden 
200973 
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Madianos 
& Stefanis 
199274 
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Madianos 
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73 2197 149 2192 Depression 3.32 6.80 DSM-IV/SCID Clinical Interview 8 
Markkula 
et al. 
201776 
Chile 2003 2010 No 672 3619 839 5052 Depression 18.57 16.61 CIDI Clinical Interview 7 
Martins et 
al. 201777 
United 
States of 
America 
2001 2012 Yes 
1 
90 43093 251 36309 Heroin 
dependence 
0.21 0.69 DSM-IV Clinical Interview 6 
McCabe et 
al. 200878 
United 
States of 
America 
1991 2001 Yes 
1 
51 42862 86 43093 Medication 0.12 0.20 Prescription drug 
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Clinical Interview 7 
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Mehta et 
al. 201579 
United 
States of 
America 
2005 2011 No 113 4836 188 4949 Depression 2.34 3.80 PHQ-9 Symptoms 7 
Min 201480 United 
States of 
America 
2005 2011 No 1246 30053 1143 28981 Distress 4.15 3.94 Kessler-6 Distress 4 
Mojtabai  
& Jorm 
201581 
United 
States of 
America 
2005 2012 Yes 
4 
4840 68308 4577 68309 Depression 7.09 6.70 DSM-IV based Clinical Interview 4 
Noorbala 
et al. 
201282 
Iran 1998 2007 No 1187 5560 6624 19370 Distress 21.35 34.20 GHQ-28 Distress 8 
Center for 
Behavioral 
Health 
Statistics 
and Quality 
201683 
United 
States of 
America 
2008 2015 Yes 
4 
12166 68736 12185 68073 General 17.70 17.90 Mental Health Survey 
Study Clinical 
Interview 
Clinical Interview 4 
Osaki et al. 
201684 
Japan 2003 2013 No 8 2547 25 4153 Alcohol 
dependence 
0.31 0.60 ICD-10 Clinical Interview 7 
Park et al. 
201585 
South Korea 2001 2011 No 36 1256 42 1066 Depression 2.87 3.94 CIDI Clinical Interview 7 
Patten et 
al. 201686 
Canada 2002 2012 No 1739 36984 1205 25113 Depression 4.70 4.80 CIDI Clinical Interview 8 
Reeves et 
al. 2011 - 
187  
United 
States of 
America 
2006 2008 Yes 
5 
17284 198678 6970 85004 Depression 8.70 8.20 PHQ-8 Symptoms 4 
Reeves et 
al. 2011 - 
287 
United 
States of 
America 
2007 2009 Yes 
5 
8124 203096 3432 87992 Distress 4.00 3.90 Kessler-6 Distress 4 
Ruiz-Perez 
et al. 
201688 
Spain 2006 2012 No 6433 28234 4532 20754 Distress 22.78 21.84 GHQ  Distress 8 
Spiers et 
al. 201689 
United 
Kingdom 
1993 2007 No 1232 8615 862 5385 General 14.30 16.01 CIS-R/ICD-10 Clinical Interview 8 
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Utzet et al. 
201690 
Spain 2005 2010 No 1578 5058 1142 3544 Distress 31.20 32.22 SF36-MHI Distress 6 
Wiberg et 
al. 2013 - 
191 
Sweden 1976 2000 Yes 
6 
31 396 46 487 Depression 7.83 9.45 DSM-IV Clinical Interview 5 
Wiberg et 
al. 2013 - 
291 
Sweden 1976 2005 Yes 
6 
26 707 54 950 Depression 3.68 5.68 Major 
depression,CPRS 
Clinical Interview 5 
Zachrisson 
et al. 
200892 
Norway 1991 2004 No 68 1537 59 1466 Eating 
disorder 
4.42 4.02 SED; DSM-IIIR/IV 
based 
Clinical Interview 5 
Zemore et 
al. 201393 
United 
States of 
America 
2000 2010 No 178 7258 235 7644 Alcohol 
dependence 
2.45 3.07 DSM-IV Clinical Interview 6 
Zivin et al. 
201394 
United 
States of 
America 
1998 2008 No 2645 16184 2004 14482 Depression 16.34 13.84 CESD elevated 
symptoms 
Symptoms 8 
Zutshi et 
al. 201195 
Australia 1998 2008 Yes 
3 
16 3010 45 3014 Bipolar 
disorder 
0.53 1.49 PRIME-MD  Symptoms 8 
 
Table 2: Univariate Meta-Analysis 
Methodological approach Odds Ratio  95% Confidence 
Interval 
Clinical diagnoses – summarized 2 (k=4)  1.046  0.998 – 1.097 
Clinical diagnoses – single 1 (k=20)  1.178  0.999 – 1.389 
Self-report symptoms/distress 1 (k=20)  1.196  1.025 – 1.398 
Mental illness condition   
General mental illness 2 (k = 4) 1.046  0.998 – 1.097 
Distress 1 (k = 13) 1.126  0.946 – 1.340 
Depression 1 (k = 15) 1.298  1.062 – 1.587 
Alcohol dependence 1 (k = 5) 1.016  0.851 – 1.215 
Drug dependence 1 (k = 3) 1.999  1.155 – 3.459 
Medication dependence2 (k = 1) 1.679  1.187 – 2.374 
Anxiety 2 (k = 1) 1.449  1.055 – 1.989 
Bipolar disorder 2 (k = 1) 2.836  1.599 – 5.029 
Eating disorders 2 (k = 1) 0.906  0.634 – 1.294 
World region   
Western Europe 1 (k = 20) 1.136  0.997 – 1.292 
North America 1 (k = 16) 1.092  0.946 – 1.261 
Oceania 1 (k = 3) 1.250  0.720 – 2.170 
Asia 1 (k = 3) 1.945  1.322 – 2.861 
Middle East2 (k = 1) 1.915  1.784 – 2.055 
South America2 (k = 1) 0.873  0.780 – 0.976 
Start decade   
1970s 1 (k = 3) 1.678  1.298 – 1.343 
1990s 1 (k = 22) 1.172  1.022 – 1.343 
2000s 1 (k = 19) 1.188  0.999 – 1.411 
End decade   
1980s 2 (k = 1) 1.839  1.650 – 2.050 
2000s 1 (k = 24) 1.142  1.004 – 1.299 
2010s 1 (k = 19) 1.272  1.070 – 1.514 
Study period   
1 to 5 years 1 (k = 5) 1.379  0.812 – 2.341 
6 to 10 years 1 (k = 25) 1.149  1.007 – 1.309 
11 to 15 years 1 (k = 9) 1.125  0.926 – 1.367 
16 to 20 years 1 (k = 3) 1.552  1.007 – 2.394 
21 and more years 1 (k = 2) 1.391  0.993 – 1.950 
Quality score   
4 to 5 1 (k = 10) 1.005  0.952 – 1.060 
6 to 7 1 (k = 23) 1.099  0.990 – 1.220 
8 to 9 1 (k = 11) 1.451  1.113 – 1.893 
1 Clustered analysis 
2 Non-clustered analysis 
Bold: Statistically significant 
 
  
Table 3: Multivariate Meta-Regression 
 Ratio of Odds 
Ratio 
95% Confidence Interval Beta estimate Standard error Beta confidence 
interval 
p-value 
Methodological approach  
Clinical diagnoses – 
summarized 2 (k=4)  
Reference 
Clinical diagnoses – single 1 
(k=20)  
0.968 0.902 - 1.039 -0.0325   0.0360    -0.1031 – 0.0381 0.3674 
Self-report 
symptoms/distress 1 (k=20)  
0.664 0.466 - 0.946 -0.4098 0.1810 -0.7646 - -0.0550 0.0236 
Mental illness condition  
General mental illness 2 (k = 
4) 
Reference 
Distress 1 (k = 13) Omitted due to redundancy3 
Depression 1 (k = 15) 0.964 0.917 - 1.013 -0.0366   0.0254    -0.0864 - 0.0133 0.1502 
Alcohol dependence 1 (k = 
5) 
0.390 0.351 - 0.433 -0.9426   0.0533   -1.0470 - -0.8381   <.0001 
Drug dependence 1 (k = 3) 0.562 0.488 - 0.647 -0.5759   0.0719    -0.7168 - -0.4350 <.0001 
Medication dependence2 (k 
= 1) 
0.745 0.522 - 1.064 -0.2940   0.1816    -0.6500 - 0.0620      0.1053 
Anxiety 2 (k = 1) 1.792 0.785 - 4.092 0.5834   0.4212     -0.2422 - 1.4089 0.1661   
Bipolar disorder 2 (k = 1) 1.779 0.974 - 3.249 0.5758   0.3075     -0.0269 - 1.1785     0.0611   
Eating disorders 2 (k = 1) 1.779 0.974 - 3.249 0.0566   0.4828     -0.8879 - 1.0029  0.9006   
World region  
Western Europe 1 (k = 20) Reference 
North America 1 (k = 16) 1.433 0.964 - 2.132 0.3601 0.2026 -0.0369 - 0.7572 0.0755 
Oceania 1 (k = 3) 1.670 0.921 - 3.030 0.5129 0.3039 -0.0828 - 1.086 0.0915 
Asia 1 (k = 3) 1.612 0.898 - 2.895 0.4776 0.2987 -0.1077 - 1.0630 0.1098 
Middle East2 (k = 1) 2.831 1.252 - 6.400 1.0406 0.4126 0.2249 - 1.8563 0.0124 
South America2 (k = 1) 0.614 0.273 - 1.382 -0.4872 0.4138 -1.2982 - 0.3238 0.2390 
Start decade       
1970s 1 (k = 3) Not selected due to model fit 
25 
 
1990s 1 (k = 22) Not selected due to model fit 
Not selected due to model fit 2000s 1 (k = 19) 
End decade  
1980s 2 (k = 1) Reference 
2000s 1 (k = 24) 0.355 0.156 - 0.805 -0.1036 0.4186 -1.8574 - -2163 0.0133 
2010s 1 (k = 19) 0.444 0.194 - 1.015 -0.8130 0.4222 -1.6406 - -0.0145 0.0542 
Study period  
1 to 5 years 1 (k = 5) Reference 
6 to 10 years 1 (k = 25) 0.633 0.394 - 1.015 -0.4578 0.2412 -0.9306 - 0.0150 0.0577 
11 to 15 years 1 (k = 9) 0.633 0.394 - 1.015 -0.1740 0.2523 -0.6685 - 0.3206 0.4905 
16 to 20 years 1 (k = 3) 1.076 0.569 - 2.036 0.0733 0.3254 -0.5644 – 0.7110 0.8217 
21 and more years 1 (k = 2) 1.417 0.528 - 3.804 0.3845 0.5038 -0.6390 – 1.3360 0.4891 
Quality score  
4 to 5 1 (k = 10) Reference 
6 to 7 1 (k = 23) 1.829 1.149 - 2.913 0.6038 0.2374 0.1385 - 1.0692 0.0110 
8 to 9 1 (k = 11) 1.530 0.952 - 2.461 0.4255 0.2423 -0.0494 - 0.9005 0.0804 
   Intercept 1.0878 0.5298 0.0494 - 2.1262 0.0400 
   Test for Residual Heterogeneity: QE(df = 21) = 479.6122, p-value < .0001 
Test of Moderators: QM(df = 22) = 472.8333, p-value < .0001 
 
1 Clustered analysis 
2 Non-clustered analysis 
3 Omitted by the statistical software  
Bold: Statistically significant 
 
 
 
 
